An ancient plant practice, a young laboratory discovery
DMT (N,N-dimethyltryptamine) was first synthesized in a lab in 1931 by chemist Richard Manske, decades before its psychoactive properties were explored. Indigenous peoples of South America, meanwhile, had been using DMT-containing plants long before Western chemistry named the molecule. A roughly 1,000-year-old ritual bundle from a rock shelter in present-day Bolivia held traces of DMT alongside harmine (the vine compound used in ayahuasca), cocaine and other substances (Miller and colleagues, PNAS, 2019). Claims that ayahuasca itself is far older, based on small ceramic vessels from Ecuador dated to around 2400 BCE, rest on an interpretation (by the Ecuadorian scholar Plutarco Naranjo, 1986) that other researchers dispute. Formal human research on smoked or injected DMT began in the 1950s under researcher Stephen Szara, then was halted, like nearly every other psychedelic, by the wave of drug-policy restriction that began in the 1960s. Psychiatrist Rick Strassman restarted formal human DMT research at the University of New Mexico in 1990, running the first new U.S. clinical studies of a psychedelic in about two decades and popularizing the drug's nickname, "the spirit molecule," through his subsequent book.
What actually happens, and why it's different from other psychedelics
Taken orally, DMT is broken down almost immediately by an enzyme in the gut (monoamine oxidase) and has essentially no effect — this is precisely why ayahuasca, the traditional Amazonian brew, combines DMT-containing plant material with a separate plant containing monoamine oxidase inhibitors (MAOIs), letting the DMT survive digestion and reach the brain (covered in its own piece in this category). Smoked, vaporized, or injected, DMT bypasses digestion entirely and produces one of the fastest, most intense psychedelic experiences known — commonly described as a complete break from ordinary reality, frequently involving vivid geometric visuals and, for many users, a subjective sense of encountering another intelligence or space entirely separate from consensus reality. Whatever its ultimate explanation, that specific, consistent phenomenological report across unconnected users is one of the more genuinely strange and well-documented features of the DMT experience.
The real dangers
Like other classic psychedelics, DMT has low toxicity and no evidence of physical addiction — its intensity comes from the depth of the experience, not from organ damage or a buildup of physical dependence. The real risks:
Overwhelming intensity with essentially no time to prepare. Because the onset is so fast and the peak so total, there's very little opportunity to "back out" or adjust once the experience begins, unlike a slower-onset drug where a user has time to reassess. This makes setting and having a sober, trusted person present especially important.
Physical safety during the peak. Users are often completely non-functional for several minutes — unaware of their surroundings, sometimes losing physical coordination entirely — which makes a safe, seated or reclined position and a sober sitter a real practical safety measure, not an optional nicety.
Psychosis risk in vulnerable individuals. As with other classic psychedelics, a personal or family history of psychosis is a serious contraindication.
MAOI interactions. Your body's monoamine oxidase (MAO) enzymes are what keep DMT short: they make swallowed DMT inactive and break down smoked or vaporized DMT within minutes. Anything that blocks those enzymes — the harmala alkaloids in ayahuasca vine or Syrian rue, or MAOI antidepressants — makes DMT stronger and much longer-lasting, and combining an MAOI with other serotonergic drugs (such as SSRIs or MDMA) can cause dangerous serotonin syndrome. This matters most for ayahuasca (see that piece).
DMT compresses the entire arc of a psychedelic experience — onset, peak, and return — into a window shorter than most people's commute. That speed is exactly what makes preparation and a safe physical setting non-negotiable rather than optional.
The research picture
DMT-specific clinical research is smaller and earlier-stage than the LSD or psilocybin pipelines, but growing — small trials have explored short-acting DMT and DMT analogues for depression, partly because its extremely brief duration is attractive for a clinical setting compared to psilocybin or LSD's much longer sessions. Some researchers have also proposed that endogenous DMT — the trace amounts the body naturally produces — may play a role in ordinary brain function, dreaming, or naturally occurring altered states, though this remains a genuinely open and actively debated area of neuroscience, not an established finding.
Try this
If you want a sense of just how compressed a DMT experience is compared to other psychedelics, compare its typical 5–15 minute smoked duration to LSD's 8–12 hours and psilocybin's 4–6 hours — the difference in scale is a big part of why the two require such different practical safety approaches.
The takeaway
DMT was synthesized in 1931 but has been used in plant form by South American peoples for at least a thousand years; smoked or vaporized, it produces one of the fastest and most intense altered states of any known drug, typically resolving in under 15 minutes. It carries the same low physical toxicity and addiction profile as other classic psychedelics, but its speed and intensity make physical safety during the peak experience — a safe position, a sober sitter — a genuinely important practical precaution rather than an optional one. Small early-stage clinical research is exploring its therapeutic potential, partly because its brevity is clinically convenient.
Try this: compare DMT's typical duration to LSD's and psilocybin's side by side to understand why its safety considerations are genuinely different from the other classic psychedelics in this category.
Sources & Further Reading
Sources
- DMT's 1931 synthesis and Strassman's 1990–1995 University of New Mexico studies reflect standard pharmacological history. Archaeology: Melanie J. Miller et al., "Chemical evidence for the use of multiple psychotropic plants in a 1,000-year-old ritual bundle from South America," PNAS, 2019 (Penn State and UC Berkeley news releases, 6 May 2019); the debate over Plutarco Naranjo's 1986 dating of Ecuadorian vessels is summarised by Chacruna Institute, "Fake News About Ayahuasca's Archeological Antiquity."
- The oral inactivity of DMT without an MAOI, and its mechanism of action, reflect standard pharmacology.
- Current DMT-analogue depression research reflects ongoing 2026 clinical-trial reporting.
Go deeper
- 📘 DMT: The Spirit Molecule — Rick Strassman (the researcher who restarted human DMT studies in 1994)
- 🌐 DanceSafe.org — harm-reduction guidance for psychedelics
- 🌐 Related pieces in this library: Ayahuasca and 5-MeO-DMT, this category — two very different plant/compound relatives of DMT